Tackling Chronic Liver Disease

Client: Hepion Pharmaceuticals

Non-alcoholic steatohepatitis (NASH) is a chronic fatty liver disease driven by a complex network of molecules called cyclophilins. Cyclophilins A, B, and D regulate disease processes such as mitochondrial damage, inflammation, and fibrosis of liver cells.

Hepion Pharmaceutical’s lead oral drug candidate, CRV431, targets all three cyclophilins by blocking their attachment to cell receptors. The goal of this animation is to educate their patients about the science and versatility of their drug.